Relma-cel shows breakthrough effects for R/R DLBCL patients

2021 CAR-T Cell Therapy Conference Special Lectures—— From CAR-T process development to clinical benefits, Relma-cel was officially held in Xuzhou, Jiangsu Province on the afternoon of March 5, and the top domestic hematological tumor masters passed The online and offline linkage will be held together

Professor Xu Kailin, Institute of Hematology, Xuzhou Medical University

The R-CHOP regimen is the "gold standard" for DLBCL treatment, but 35%-40% of patients are resistant or relapsed to traditional R-CHOP ^{[ 1]} , R/R DLBCL patients have a poor prognosis ^{[2 ]} , alternative treatment options Very restricted

Professor Hu Yongxian said in his report that CAR-T cell therapy has become the focus of research in the field of tumor treatment

Professor Hu Yongxian, the First Affiliated Hospital of Zhejiang University School of Medicine

Relma-cel: Advanced product and process design

Relma-cel is a self-developed autologous CAR-T cell product targeting CD19 based on the Liso-cel (JCAR017) process platform of JUNO, USA

Ricky Orlens uses 4-1BB as the costimulatory domain

In addition, Ricky Orense adopts advanced and mature production processes and technologies such as T cell purification, cryopreservation, lentiviral vectors, dynamic amplification, etc.

Relma-cel: RELIANCE trial, bringing new options for R/R DLBCL patients

The results of the critical clinical trial (RELIANCE) phase II of Rigi Orenza have been announced at the 2020 ASH conference ^{[5 ]} .

Data as of June 17, 2020, among 58 patients with evaluable effectiveness, the best ORR was 75.

The median time for patients to reach CR for the first time was 0.

Relma-cel: excellent safety performance

Safety analysis showed that among 59 patients who received treatment, 28 patients (47.

The RELIANCE trial is the first CAR-T product made in China that meets the production standards for clinical trials and is used in clinical research for patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in China

In the subsequent discussion session, Professor Huang Yihong from the Affiliated Hospital of Xuzhou Medical University had a lively discussion with Professor Hu Yongxian on topics such as RELIANCE research data and the application advantages of Ruiji Orenx, which further deepened everyone's understanding of this CAR-T product

In view of the mature production technology of CD19 CAR-T targeted by Ruiji Orenza and the excellent clinical data released by the 2020 ASH conference, we believe that Ruiji Orenza will bring new treatment options to China's R/R DLBCL in the future

[1].

[2].

[3].
Kawalekar OU, et al.
Immunity.
2016;44(2):380-390.

[4].
Long AH, et al.
Nat Med.
2015;21(5):581-590.

[5].
Zhu J, et al.
ASH 2020.
Abstracts 1186